MX363334B - Una forma cristalina anhidra de cabazitaxel, procedimiento para la preparación y composiciones farmacéuticas del mismo. - Google Patents

Una forma cristalina anhidra de cabazitaxel, procedimiento para la preparación y composiciones farmacéuticas del mismo.

Info

Publication number
MX363334B
MX363334B MX2016005231A MX2016005231A MX363334B MX 363334 B MX363334 B MX 363334B MX 2016005231 A MX2016005231 A MX 2016005231A MX 2016005231 A MX2016005231 A MX 2016005231A MX 363334 B MX363334 B MX 363334B
Authority
MX
Mexico
Prior art keywords
cabazitaxel
preparation
pharmaceutical compositions
anhydrous form
crystalline anhydrous
Prior art date
Application number
MX2016005231A
Other languages
English (en)
Other versions
MX2016005231A (es
Inventor
Andrea Gambini
Daniele Ciceri
Cabri Walter
Domenighini Luca
PETERLONGO Federico
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49447494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX363334(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indena Spa filed Critical Indena Spa
Publication of MX2016005231A publication Critical patent/MX2016005231A/es
Publication of MX363334B publication Critical patent/MX363334B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se refiere a una novedosa forma cristalina anhidra de Cabazitaxel de la fórmula (I), designada como la forma H; (ver Fórmula) otro objetivo de la presente invención es un procedimiento para la preparación de la forma H antes mencionada, por medio de la recristalización de Cabazitaxel a partir de una mezcla de decanoil- y octanoil triglicéridos o a partir de trioctanoato de glicerol; la forma H de Cabazitaxel es útil para la preparación de Cabazitaxel, sales de Cabazitaxel y formas polimórficas de la misma; también es particularmente útil como un medicamento, en especial para el tratamiento de cánceres.
MX2016005231A 2013-10-23 2014-10-09 Una forma cristalina anhidra de cabazitaxel, procedimiento para la preparación y composiciones farmacéuticas del mismo. MX363334B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130189949 EP2865675A1 (en) 2013-10-23 2013-10-23 A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
PCT/EP2014/071601 WO2015058961A1 (en) 2013-10-23 2014-10-09 A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
MX2016005231A MX2016005231A (es) 2016-08-11
MX363334B true MX363334B (es) 2019-03-19

Family

ID=49447494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005231A MX363334B (es) 2013-10-23 2014-10-09 Una forma cristalina anhidra de cabazitaxel, procedimiento para la preparación y composiciones farmacéuticas del mismo.

Country Status (20)

Country Link
US (1) US9586919B2 (es)
EP (2) EP2865675A1 (es)
JP (2) JP2016534065A (es)
KR (2) KR20210158417A (es)
CN (1) CN105849093A (es)
AU (1) AU2014339222B2 (es)
BR (1) BR112016007646B1 (es)
CA (1) CA2928305C (es)
CL (1) CL2016000951A1 (es)
DK (1) DK3060556T3 (es)
ES (1) ES2645478T3 (es)
HU (1) HUE035010T2 (es)
IL (1) IL245260B (es)
MX (1) MX363334B (es)
PL (1) PL3060556T3 (es)
PT (1) PT3060556T (es)
RU (1) RU2672110C2 (es)
SG (1) SG11201603168WA (es)
SI (1) SI3060556T1 (es)
WO (1) WO2015058961A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017207821A1 (en) 2016-01-15 2018-07-19 Zhuhai Beihai Biotech Co., Ltd. Compositions and formulations including cabazitaxel and human serum albumin
WO2019204738A1 (en) 2018-04-20 2019-10-24 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of cabazitaxel
WO2020249507A1 (en) * 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
EP2094084A4 (en) * 2006-10-20 2010-01-13 Scinopharm Singapore Pte Ltd PROCESS FOR PREPARING CRYSTALLINE WATER-FREE DOCETAXEL
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2688877B1 (en) 2011-04-12 2017-03-08 Teva Pharmaceuticals International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
EP2548905A1 (de) 2011-07-18 2013-01-23 Bayer MaterialScience AG Verfahren zur Aktivierung von Doppelmetallcyanidkatalysatoren zur Herstellung von Polyetherpolyolen
TWI526437B (zh) 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
JP6025861B2 (ja) 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
WO2013134534A2 (en) 2012-03-08 2013-09-12 Plus Chemicals S.A. Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (zh) 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102898406B (zh) * 2012-11-02 2014-12-03 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法

Also Published As

Publication number Publication date
SI3060556T1 (sl) 2017-10-30
EP3060556B1 (en) 2017-08-02
HUE035010T2 (en) 2018-03-28
AU2014339222B2 (en) 2017-12-14
CN105849093A (zh) 2016-08-10
US9586919B2 (en) 2017-03-07
CL2016000951A1 (es) 2016-11-25
BR112016007646A2 (pt) 2017-08-01
ES2645478T3 (es) 2017-12-05
BR112016007646B1 (pt) 2022-12-27
AU2014339222A1 (en) 2016-05-12
RU2016115538A (ru) 2017-10-26
CA2928305C (en) 2021-06-15
KR20210158417A (ko) 2021-12-30
JP2019055989A (ja) 2019-04-11
MX2016005231A (es) 2016-08-11
RU2016115538A3 (es) 2018-06-14
EP2865675A1 (en) 2015-04-29
PL3060556T3 (pl) 2018-01-31
IL245260B (en) 2018-11-29
SG11201603168WA (en) 2016-05-30
EP3060556A1 (en) 2016-08-31
DK3060556T3 (en) 2017-09-04
JP6698803B2 (ja) 2020-05-27
WO2015058961A1 (en) 2015-04-30
PT3060556T (pt) 2017-11-10
US20160244420A1 (en) 2016-08-25
RU2672110C2 (ru) 2018-11-12
IL245260A0 (en) 2016-06-30
CA2928305A1 (en) 2015-04-30
KR20160063356A (ko) 2016-06-03
JP2016534065A (ja) 2016-11-04

Similar Documents

Publication Publication Date Title
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
CY1118678T1 (el) Παραγωγα καρβοξαμιδιου χλωρο-πυραζινης χρησιμα για την θεραπευτικη αντιμετωπιση ασθενειων που ευνοουνται απο την ανεπαρκη ενυδατωση του βλεννογονου
IN2014MN02106A (es)
MD20160017A2 (ro) Polimorf al inhibitorilor SYK
MX2015005286A (es) Procedimiento para la preparación de derivados del ácido biliar.
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MX368703B (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
EA033513B1 (ru) Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
TN2013000434A1 (en) Novel imidazole derivatives useful for the treatment of arthritis
UA110354C2 (uk) Противірусні сполуки
PH12015502524A1 (en) New somatostatin receptor subtype 4 (sstr4) agonists
TW201240990A (en) Antiviral compounds
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
IN2014MN02459A (es)
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
IN2014CN04530A (es)
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
IN2014MN01521A (es)
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
MX364400B (es) Compuestos de tetraciclina.
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
MX363334B (es) Una forma cristalina anhidra de cabazitaxel, procedimiento para la preparación y composiciones farmacéuticas del mismo.